Research ArticleArticle
Open Access
Treatment of Psoriasis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
Kristina Callis Duffin, Luis Daniel Mazzuoccolo, María Julia Cura, Maria Esposito, Anthony P. Fernandez, Paolo Gisondi, Alessandro Giunta, Tom Hillary, Stefano Piaserico, James Solomon and Joseph F. Merola
The Journal of Rheumatology November 2022, jrheum.220316; DOI: https://doi.org/10.3899/jrheum.220316
Kristina Callis Duffin
K. Callis Duffin, MD, Department of Dermatology, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA; L.D. Mazzuoccolo, MD, MPH, M.J. Cura, MD, Department of Dermatology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; M. Esposito, MD, Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy; A.P. Fernandez, MD, PhD, Departments of Dermatology and Pathology, Cleveland Clinic, Cleveland, Ohio, USA; P. Gisondi, MD, Section of Dermatology and Venereology, University of Verona, Verona, Italy; A. Giunta, MD, Department of Dermatology, University of Rome Tor Vergata, Rome, Italy; T. Hillary, MD, Department of Dermatology, University Hospitals Leuven, Leuven, Belgium; S. Piaserico, MD, PhD, Unit of Dermatology, Department of Medicine, University of Padua, Padova, Italy; J.A. Solomon, MD, PhD, University Central Florida College of Medicine, and Florida State University College of Medicine, Orlando, Florida, and Carle-Illinois College of Medicine, Urbana, Illinois, USA; J.F. Merola, MD, MMSc, Division of Rheumatology and Immunology, Department of Dermatology and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. KCD received grants or is an investigator for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, BMS, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, and BI; is on the speaker's bureau for Novartis (nonpromotional only); and is on the consultant/advisory board for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, BMS, Stiefel, Novartis, Pfizer, Sienna, UCB, Ortho Dermatologic, and BI. LDM is a paid speaker for AbbVie, Elli Lilly, Novartis, Amgen, Janssen, UCB, and BI. MJC is a paid speaker for AbbVie, Janssen, and UCB. ME is a consultant/advisory board/invited speaker for Almirall, AbbVie, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Sanofi, and UCB. APF has received grants or is an investigator for Pfizer, Corbus, Mallinckrodt, AbbVie, and Novartis; on the speaker's bureau (nonpromotional only) for AbbVie, Novartis, Kyowa Kirin, and Mallinckrodt; and is on the consultant/advisory board for AbbVie, Alexion, BMS, Mallinckrodt, Novartis, and UCB. PG served as speaker and/or participated in advisory boards for AbbVie, Almirall, Amgen, Eli Lilly, Janssen, Novartis, Sanofi, Pfizer, and UCB. AG received grants or is an investigator for Biogen and Lilly; and is a consultant/advisory board/speaker for AbbVie, Almirall, Amgen, Biogen, Lilly, Sandoz, and UCB. TH has received grants or is an investigator/consultant for Amgen, AbbVie, Biogen, Celgene, Eli Lilly, Janssen, BMS, Novartis, Sandoz, Pfizer, UCB, Roche, and BI. SP is a consultant and/or speaker for AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, and UCB. JS is a consultant and/or investigator for Eli Lilly, GLG, LEO Pharma, Merck, Pfizer, Galderma, Parexel, UCB, Hedgepath, Mavis, BI, AbbVie, inVentiv, Sun Pharmaceutical, Mayne Pharma, Incyte, Arena, and PellePharm. JFM is a consultant and/or investigator for Merck, BMS, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres, and LEO Pharma. Address correspondence to Dr. K. Callis Duffin, Department of Dermatology, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT 84103, USA. Email: kristina.duffin@hsc.utah.edu. Accepted for publication May 12, 2022.
Luis Daniel Mazzuoccolo
K. Callis Duffin, MD, Department of Dermatology, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA; L.D. Mazzuoccolo, MD, MPH, M.J. Cura, MD, Department of Dermatology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; M. Esposito, MD, Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy; A.P. Fernandez, MD, PhD, Departments of Dermatology and Pathology, Cleveland Clinic, Cleveland, Ohio, USA; P. Gisondi, MD, Section of Dermatology and Venereology, University of Verona, Verona, Italy; A. Giunta, MD, Department of Dermatology, University of Rome Tor Vergata, Rome, Italy; T. Hillary, MD, Department of Dermatology, University Hospitals Leuven, Leuven, Belgium; S. Piaserico, MD, PhD, Unit of Dermatology, Department of Medicine, University of Padua, Padova, Italy; J.A. Solomon, MD, PhD, University Central Florida College of Medicine, and Florida State University College of Medicine, Orlando, Florida, and Carle-Illinois College of Medicine, Urbana, Illinois, USA; J.F. Merola, MD, MMSc, Division of Rheumatology and Immunology, Department of Dermatology and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. KCD received grants or is an investigator for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, BMS, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, and BI; is on the speaker's bureau for Novartis (nonpromotional only); and is on the consultant/advisory board for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, BMS, Stiefel, Novartis, Pfizer, Sienna, UCB, Ortho Dermatologic, and BI. LDM is a paid speaker for AbbVie, Elli Lilly, Novartis, Amgen, Janssen, UCB, and BI. MJC is a paid speaker for AbbVie, Janssen, and UCB. ME is a consultant/advisory board/invited speaker for Almirall, AbbVie, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Sanofi, and UCB. APF has received grants or is an investigator for Pfizer, Corbus, Mallinckrodt, AbbVie, and Novartis; on the speaker's bureau (nonpromotional only) for AbbVie, Novartis, Kyowa Kirin, and Mallinckrodt; and is on the consultant/advisory board for AbbVie, Alexion, BMS, Mallinckrodt, Novartis, and UCB. PG served as speaker and/or participated in advisory boards for AbbVie, Almirall, Amgen, Eli Lilly, Janssen, Novartis, Sanofi, Pfizer, and UCB. AG received grants or is an investigator for Biogen and Lilly; and is a consultant/advisory board/speaker for AbbVie, Almirall, Amgen, Biogen, Lilly, Sandoz, and UCB. TH has received grants or is an investigator/consultant for Amgen, AbbVie, Biogen, Celgene, Eli Lilly, Janssen, BMS, Novartis, Sandoz, Pfizer, UCB, Roche, and BI. SP is a consultant and/or speaker for AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, and UCB. JS is a consultant and/or investigator for Eli Lilly, GLG, LEO Pharma, Merck, Pfizer, Galderma, Parexel, UCB, Hedgepath, Mavis, BI, AbbVie, inVentiv, Sun Pharmaceutical, Mayne Pharma, Incyte, Arena, and PellePharm. JFM is a consultant and/or investigator for Merck, BMS, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres, and LEO Pharma. Address correspondence to Dr. K. Callis Duffin, Department of Dermatology, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT 84103, USA. Email: kristina.duffin@hsc.utah.edu. Accepted for publication May 12, 2022.
María Julia Cura
K. Callis Duffin, MD, Department of Dermatology, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA; L.D. Mazzuoccolo, MD, MPH, M.J. Cura, MD, Department of Dermatology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; M. Esposito, MD, Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy; A.P. Fernandez, MD, PhD, Departments of Dermatology and Pathology, Cleveland Clinic, Cleveland, Ohio, USA; P. Gisondi, MD, Section of Dermatology and Venereology, University of Verona, Verona, Italy; A. Giunta, MD, Department of Dermatology, University of Rome Tor Vergata, Rome, Italy; T. Hillary, MD, Department of Dermatology, University Hospitals Leuven, Leuven, Belgium; S. Piaserico, MD, PhD, Unit of Dermatology, Department of Medicine, University of Padua, Padova, Italy; J.A. Solomon, MD, PhD, University Central Florida College of Medicine, and Florida State University College of Medicine, Orlando, Florida, and Carle-Illinois College of Medicine, Urbana, Illinois, USA; J.F. Merola, MD, MMSc, Division of Rheumatology and Immunology, Department of Dermatology and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. KCD received grants or is an investigator for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, BMS, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, and BI; is on the speaker's bureau for Novartis (nonpromotional only); and is on the consultant/advisory board for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, BMS, Stiefel, Novartis, Pfizer, Sienna, UCB, Ortho Dermatologic, and BI. LDM is a paid speaker for AbbVie, Elli Lilly, Novartis, Amgen, Janssen, UCB, and BI. MJC is a paid speaker for AbbVie, Janssen, and UCB. ME is a consultant/advisory board/invited speaker for Almirall, AbbVie, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Sanofi, and UCB. APF has received grants or is an investigator for Pfizer, Corbus, Mallinckrodt, AbbVie, and Novartis; on the speaker's bureau (nonpromotional only) for AbbVie, Novartis, Kyowa Kirin, and Mallinckrodt; and is on the consultant/advisory board for AbbVie, Alexion, BMS, Mallinckrodt, Novartis, and UCB. PG served as speaker and/or participated in advisory boards for AbbVie, Almirall, Amgen, Eli Lilly, Janssen, Novartis, Sanofi, Pfizer, and UCB. AG received grants or is an investigator for Biogen and Lilly; and is a consultant/advisory board/speaker for AbbVie, Almirall, Amgen, Biogen, Lilly, Sandoz, and UCB. TH has received grants or is an investigator/consultant for Amgen, AbbVie, Biogen, Celgene, Eli Lilly, Janssen, BMS, Novartis, Sandoz, Pfizer, UCB, Roche, and BI. SP is a consultant and/or speaker for AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, and UCB. JS is a consultant and/or investigator for Eli Lilly, GLG, LEO Pharma, Merck, Pfizer, Galderma, Parexel, UCB, Hedgepath, Mavis, BI, AbbVie, inVentiv, Sun Pharmaceutical, Mayne Pharma, Incyte, Arena, and PellePharm. JFM is a consultant and/or investigator for Merck, BMS, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres, and LEO Pharma. Address correspondence to Dr. K. Callis Duffin, Department of Dermatology, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT 84103, USA. Email: kristina.duffin@hsc.utah.edu. Accepted for publication May 12, 2022.
Maria Esposito
K. Callis Duffin, MD, Department of Dermatology, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA; L.D. Mazzuoccolo, MD, MPH, M.J. Cura, MD, Department of Dermatology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; M. Esposito, MD, Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy; A.P. Fernandez, MD, PhD, Departments of Dermatology and Pathology, Cleveland Clinic, Cleveland, Ohio, USA; P. Gisondi, MD, Section of Dermatology and Venereology, University of Verona, Verona, Italy; A. Giunta, MD, Department of Dermatology, University of Rome Tor Vergata, Rome, Italy; T. Hillary, MD, Department of Dermatology, University Hospitals Leuven, Leuven, Belgium; S. Piaserico, MD, PhD, Unit of Dermatology, Department of Medicine, University of Padua, Padova, Italy; J.A. Solomon, MD, PhD, University Central Florida College of Medicine, and Florida State University College of Medicine, Orlando, Florida, and Carle-Illinois College of Medicine, Urbana, Illinois, USA; J.F. Merola, MD, MMSc, Division of Rheumatology and Immunology, Department of Dermatology and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. KCD received grants or is an investigator for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, BMS, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, and BI; is on the speaker's bureau for Novartis (nonpromotional only); and is on the consultant/advisory board for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, BMS, Stiefel, Novartis, Pfizer, Sienna, UCB, Ortho Dermatologic, and BI. LDM is a paid speaker for AbbVie, Elli Lilly, Novartis, Amgen, Janssen, UCB, and BI. MJC is a paid speaker for AbbVie, Janssen, and UCB. ME is a consultant/advisory board/invited speaker for Almirall, AbbVie, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Sanofi, and UCB. APF has received grants or is an investigator for Pfizer, Corbus, Mallinckrodt, AbbVie, and Novartis; on the speaker's bureau (nonpromotional only) for AbbVie, Novartis, Kyowa Kirin, and Mallinckrodt; and is on the consultant/advisory board for AbbVie, Alexion, BMS, Mallinckrodt, Novartis, and UCB. PG served as speaker and/or participated in advisory boards for AbbVie, Almirall, Amgen, Eli Lilly, Janssen, Novartis, Sanofi, Pfizer, and UCB. AG received grants or is an investigator for Biogen and Lilly; and is a consultant/advisory board/speaker for AbbVie, Almirall, Amgen, Biogen, Lilly, Sandoz, and UCB. TH has received grants or is an investigator/consultant for Amgen, AbbVie, Biogen, Celgene, Eli Lilly, Janssen, BMS, Novartis, Sandoz, Pfizer, UCB, Roche, and BI. SP is a consultant and/or speaker for AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, and UCB. JS is a consultant and/or investigator for Eli Lilly, GLG, LEO Pharma, Merck, Pfizer, Galderma, Parexel, UCB, Hedgepath, Mavis, BI, AbbVie, inVentiv, Sun Pharmaceutical, Mayne Pharma, Incyte, Arena, and PellePharm. JFM is a consultant and/or investigator for Merck, BMS, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres, and LEO Pharma. Address correspondence to Dr. K. Callis Duffin, Department of Dermatology, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT 84103, USA. Email: kristina.duffin@hsc.utah.edu. Accepted for publication May 12, 2022.
Anthony P. Fernandez
K. Callis Duffin, MD, Department of Dermatology, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA; L.D. Mazzuoccolo, MD, MPH, M.J. Cura, MD, Department of Dermatology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; M. Esposito, MD, Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy; A.P. Fernandez, MD, PhD, Departments of Dermatology and Pathology, Cleveland Clinic, Cleveland, Ohio, USA; P. Gisondi, MD, Section of Dermatology and Venereology, University of Verona, Verona, Italy; A. Giunta, MD, Department of Dermatology, University of Rome Tor Vergata, Rome, Italy; T. Hillary, MD, Department of Dermatology, University Hospitals Leuven, Leuven, Belgium; S. Piaserico, MD, PhD, Unit of Dermatology, Department of Medicine, University of Padua, Padova, Italy; J.A. Solomon, MD, PhD, University Central Florida College of Medicine, and Florida State University College of Medicine, Orlando, Florida, and Carle-Illinois College of Medicine, Urbana, Illinois, USA; J.F. Merola, MD, MMSc, Division of Rheumatology and Immunology, Department of Dermatology and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. KCD received grants or is an investigator for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, BMS, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, and BI; is on the speaker's bureau for Novartis (nonpromotional only); and is on the consultant/advisory board for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, BMS, Stiefel, Novartis, Pfizer, Sienna, UCB, Ortho Dermatologic, and BI. LDM is a paid speaker for AbbVie, Elli Lilly, Novartis, Amgen, Janssen, UCB, and BI. MJC is a paid speaker for AbbVie, Janssen, and UCB. ME is a consultant/advisory board/invited speaker for Almirall, AbbVie, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Sanofi, and UCB. APF has received grants or is an investigator for Pfizer, Corbus, Mallinckrodt, AbbVie, and Novartis; on the speaker's bureau (nonpromotional only) for AbbVie, Novartis, Kyowa Kirin, and Mallinckrodt; and is on the consultant/advisory board for AbbVie, Alexion, BMS, Mallinckrodt, Novartis, and UCB. PG served as speaker and/or participated in advisory boards for AbbVie, Almirall, Amgen, Eli Lilly, Janssen, Novartis, Sanofi, Pfizer, and UCB. AG received grants or is an investigator for Biogen and Lilly; and is a consultant/advisory board/speaker for AbbVie, Almirall, Amgen, Biogen, Lilly, Sandoz, and UCB. TH has received grants or is an investigator/consultant for Amgen, AbbVie, Biogen, Celgene, Eli Lilly, Janssen, BMS, Novartis, Sandoz, Pfizer, UCB, Roche, and BI. SP is a consultant and/or speaker for AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, and UCB. JS is a consultant and/or investigator for Eli Lilly, GLG, LEO Pharma, Merck, Pfizer, Galderma, Parexel, UCB, Hedgepath, Mavis, BI, AbbVie, inVentiv, Sun Pharmaceutical, Mayne Pharma, Incyte, Arena, and PellePharm. JFM is a consultant and/or investigator for Merck, BMS, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres, and LEO Pharma. Address correspondence to Dr. K. Callis Duffin, Department of Dermatology, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT 84103, USA. Email: kristina.duffin@hsc.utah.edu. Accepted for publication May 12, 2022.
Paolo Gisondi
K. Callis Duffin, MD, Department of Dermatology, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA; L.D. Mazzuoccolo, MD, MPH, M.J. Cura, MD, Department of Dermatology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; M. Esposito, MD, Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy; A.P. Fernandez, MD, PhD, Departments of Dermatology and Pathology, Cleveland Clinic, Cleveland, Ohio, USA; P. Gisondi, MD, Section of Dermatology and Venereology, University of Verona, Verona, Italy; A. Giunta, MD, Department of Dermatology, University of Rome Tor Vergata, Rome, Italy; T. Hillary, MD, Department of Dermatology, University Hospitals Leuven, Leuven, Belgium; S. Piaserico, MD, PhD, Unit of Dermatology, Department of Medicine, University of Padua, Padova, Italy; J.A. Solomon, MD, PhD, University Central Florida College of Medicine, and Florida State University College of Medicine, Orlando, Florida, and Carle-Illinois College of Medicine, Urbana, Illinois, USA; J.F. Merola, MD, MMSc, Division of Rheumatology and Immunology, Department of Dermatology and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. KCD received grants or is an investigator for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, BMS, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, and BI; is on the speaker's bureau for Novartis (nonpromotional only); and is on the consultant/advisory board for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, BMS, Stiefel, Novartis, Pfizer, Sienna, UCB, Ortho Dermatologic, and BI. LDM is a paid speaker for AbbVie, Elli Lilly, Novartis, Amgen, Janssen, UCB, and BI. MJC is a paid speaker for AbbVie, Janssen, and UCB. ME is a consultant/advisory board/invited speaker for Almirall, AbbVie, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Sanofi, and UCB. APF has received grants or is an investigator for Pfizer, Corbus, Mallinckrodt, AbbVie, and Novartis; on the speaker's bureau (nonpromotional only) for AbbVie, Novartis, Kyowa Kirin, and Mallinckrodt; and is on the consultant/advisory board for AbbVie, Alexion, BMS, Mallinckrodt, Novartis, and UCB. PG served as speaker and/or participated in advisory boards for AbbVie, Almirall, Amgen, Eli Lilly, Janssen, Novartis, Sanofi, Pfizer, and UCB. AG received grants or is an investigator for Biogen and Lilly; and is a consultant/advisory board/speaker for AbbVie, Almirall, Amgen, Biogen, Lilly, Sandoz, and UCB. TH has received grants or is an investigator/consultant for Amgen, AbbVie, Biogen, Celgene, Eli Lilly, Janssen, BMS, Novartis, Sandoz, Pfizer, UCB, Roche, and BI. SP is a consultant and/or speaker for AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, and UCB. JS is a consultant and/or investigator for Eli Lilly, GLG, LEO Pharma, Merck, Pfizer, Galderma, Parexel, UCB, Hedgepath, Mavis, BI, AbbVie, inVentiv, Sun Pharmaceutical, Mayne Pharma, Incyte, Arena, and PellePharm. JFM is a consultant and/or investigator for Merck, BMS, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres, and LEO Pharma. Address correspondence to Dr. K. Callis Duffin, Department of Dermatology, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT 84103, USA. Email: kristina.duffin@hsc.utah.edu. Accepted for publication May 12, 2022.
Alessandro Giunta
K. Callis Duffin, MD, Department of Dermatology, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA; L.D. Mazzuoccolo, MD, MPH, M.J. Cura, MD, Department of Dermatology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; M. Esposito, MD, Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy; A.P. Fernandez, MD, PhD, Departments of Dermatology and Pathology, Cleveland Clinic, Cleveland, Ohio, USA; P. Gisondi, MD, Section of Dermatology and Venereology, University of Verona, Verona, Italy; A. Giunta, MD, Department of Dermatology, University of Rome Tor Vergata, Rome, Italy; T. Hillary, MD, Department of Dermatology, University Hospitals Leuven, Leuven, Belgium; S. Piaserico, MD, PhD, Unit of Dermatology, Department of Medicine, University of Padua, Padova, Italy; J.A. Solomon, MD, PhD, University Central Florida College of Medicine, and Florida State University College of Medicine, Orlando, Florida, and Carle-Illinois College of Medicine, Urbana, Illinois, USA; J.F. Merola, MD, MMSc, Division of Rheumatology and Immunology, Department of Dermatology and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. KCD received grants or is an investigator for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, BMS, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, and BI; is on the speaker's bureau for Novartis (nonpromotional only); and is on the consultant/advisory board for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, BMS, Stiefel, Novartis, Pfizer, Sienna, UCB, Ortho Dermatologic, and BI. LDM is a paid speaker for AbbVie, Elli Lilly, Novartis, Amgen, Janssen, UCB, and BI. MJC is a paid speaker for AbbVie, Janssen, and UCB. ME is a consultant/advisory board/invited speaker for Almirall, AbbVie, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Sanofi, and UCB. APF has received grants or is an investigator for Pfizer, Corbus, Mallinckrodt, AbbVie, and Novartis; on the speaker's bureau (nonpromotional only) for AbbVie, Novartis, Kyowa Kirin, and Mallinckrodt; and is on the consultant/advisory board for AbbVie, Alexion, BMS, Mallinckrodt, Novartis, and UCB. PG served as speaker and/or participated in advisory boards for AbbVie, Almirall, Amgen, Eli Lilly, Janssen, Novartis, Sanofi, Pfizer, and UCB. AG received grants or is an investigator for Biogen and Lilly; and is a consultant/advisory board/speaker for AbbVie, Almirall, Amgen, Biogen, Lilly, Sandoz, and UCB. TH has received grants or is an investigator/consultant for Amgen, AbbVie, Biogen, Celgene, Eli Lilly, Janssen, BMS, Novartis, Sandoz, Pfizer, UCB, Roche, and BI. SP is a consultant and/or speaker for AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, and UCB. JS is a consultant and/or investigator for Eli Lilly, GLG, LEO Pharma, Merck, Pfizer, Galderma, Parexel, UCB, Hedgepath, Mavis, BI, AbbVie, inVentiv, Sun Pharmaceutical, Mayne Pharma, Incyte, Arena, and PellePharm. JFM is a consultant and/or investigator for Merck, BMS, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres, and LEO Pharma. Address correspondence to Dr. K. Callis Duffin, Department of Dermatology, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT 84103, USA. Email: kristina.duffin@hsc.utah.edu. Accepted for publication May 12, 2022.
Tom Hillary
K. Callis Duffin, MD, Department of Dermatology, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA; L.D. Mazzuoccolo, MD, MPH, M.J. Cura, MD, Department of Dermatology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; M. Esposito, MD, Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy; A.P. Fernandez, MD, PhD, Departments of Dermatology and Pathology, Cleveland Clinic, Cleveland, Ohio, USA; P. Gisondi, MD, Section of Dermatology and Venereology, University of Verona, Verona, Italy; A. Giunta, MD, Department of Dermatology, University of Rome Tor Vergata, Rome, Italy; T. Hillary, MD, Department of Dermatology, University Hospitals Leuven, Leuven, Belgium; S. Piaserico, MD, PhD, Unit of Dermatology, Department of Medicine, University of Padua, Padova, Italy; J.A. Solomon, MD, PhD, University Central Florida College of Medicine, and Florida State University College of Medicine, Orlando, Florida, and Carle-Illinois College of Medicine, Urbana, Illinois, USA; J.F. Merola, MD, MMSc, Division of Rheumatology and Immunology, Department of Dermatology and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. KCD received grants or is an investigator for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, BMS, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, and BI; is on the speaker's bureau for Novartis (nonpromotional only); and is on the consultant/advisory board for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, BMS, Stiefel, Novartis, Pfizer, Sienna, UCB, Ortho Dermatologic, and BI. LDM is a paid speaker for AbbVie, Elli Lilly, Novartis, Amgen, Janssen, UCB, and BI. MJC is a paid speaker for AbbVie, Janssen, and UCB. ME is a consultant/advisory board/invited speaker for Almirall, AbbVie, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Sanofi, and UCB. APF has received grants or is an investigator for Pfizer, Corbus, Mallinckrodt, AbbVie, and Novartis; on the speaker's bureau (nonpromotional only) for AbbVie, Novartis, Kyowa Kirin, and Mallinckrodt; and is on the consultant/advisory board for AbbVie, Alexion, BMS, Mallinckrodt, Novartis, and UCB. PG served as speaker and/or participated in advisory boards for AbbVie, Almirall, Amgen, Eli Lilly, Janssen, Novartis, Sanofi, Pfizer, and UCB. AG received grants or is an investigator for Biogen and Lilly; and is a consultant/advisory board/speaker for AbbVie, Almirall, Amgen, Biogen, Lilly, Sandoz, and UCB. TH has received grants or is an investigator/consultant for Amgen, AbbVie, Biogen, Celgene, Eli Lilly, Janssen, BMS, Novartis, Sandoz, Pfizer, UCB, Roche, and BI. SP is a consultant and/or speaker for AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, and UCB. JS is a consultant and/or investigator for Eli Lilly, GLG, LEO Pharma, Merck, Pfizer, Galderma, Parexel, UCB, Hedgepath, Mavis, BI, AbbVie, inVentiv, Sun Pharmaceutical, Mayne Pharma, Incyte, Arena, and PellePharm. JFM is a consultant and/or investigator for Merck, BMS, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres, and LEO Pharma. Address correspondence to Dr. K. Callis Duffin, Department of Dermatology, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT 84103, USA. Email: kristina.duffin@hsc.utah.edu. Accepted for publication May 12, 2022.
Stefano Piaserico
K. Callis Duffin, MD, Department of Dermatology, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA; L.D. Mazzuoccolo, MD, MPH, M.J. Cura, MD, Department of Dermatology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; M. Esposito, MD, Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy; A.P. Fernandez, MD, PhD, Departments of Dermatology and Pathology, Cleveland Clinic, Cleveland, Ohio, USA; P. Gisondi, MD, Section of Dermatology and Venereology, University of Verona, Verona, Italy; A. Giunta, MD, Department of Dermatology, University of Rome Tor Vergata, Rome, Italy; T. Hillary, MD, Department of Dermatology, University Hospitals Leuven, Leuven, Belgium; S. Piaserico, MD, PhD, Unit of Dermatology, Department of Medicine, University of Padua, Padova, Italy; J.A. Solomon, MD, PhD, University Central Florida College of Medicine, and Florida State University College of Medicine, Orlando, Florida, and Carle-Illinois College of Medicine, Urbana, Illinois, USA; J.F. Merola, MD, MMSc, Division of Rheumatology and Immunology, Department of Dermatology and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. KCD received grants or is an investigator for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, BMS, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, and BI; is on the speaker's bureau for Novartis (nonpromotional only); and is on the consultant/advisory board for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, BMS, Stiefel, Novartis, Pfizer, Sienna, UCB, Ortho Dermatologic, and BI. LDM is a paid speaker for AbbVie, Elli Lilly, Novartis, Amgen, Janssen, UCB, and BI. MJC is a paid speaker for AbbVie, Janssen, and UCB. ME is a consultant/advisory board/invited speaker for Almirall, AbbVie, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Sanofi, and UCB. APF has received grants or is an investigator for Pfizer, Corbus, Mallinckrodt, AbbVie, and Novartis; on the speaker's bureau (nonpromotional only) for AbbVie, Novartis, Kyowa Kirin, and Mallinckrodt; and is on the consultant/advisory board for AbbVie, Alexion, BMS, Mallinckrodt, Novartis, and UCB. PG served as speaker and/or participated in advisory boards for AbbVie, Almirall, Amgen, Eli Lilly, Janssen, Novartis, Sanofi, Pfizer, and UCB. AG received grants or is an investigator for Biogen and Lilly; and is a consultant/advisory board/speaker for AbbVie, Almirall, Amgen, Biogen, Lilly, Sandoz, and UCB. TH has received grants or is an investigator/consultant for Amgen, AbbVie, Biogen, Celgene, Eli Lilly, Janssen, BMS, Novartis, Sandoz, Pfizer, UCB, Roche, and BI. SP is a consultant and/or speaker for AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, and UCB. JS is a consultant and/or investigator for Eli Lilly, GLG, LEO Pharma, Merck, Pfizer, Galderma, Parexel, UCB, Hedgepath, Mavis, BI, AbbVie, inVentiv, Sun Pharmaceutical, Mayne Pharma, Incyte, Arena, and PellePharm. JFM is a consultant and/or investigator for Merck, BMS, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres, and LEO Pharma. Address correspondence to Dr. K. Callis Duffin, Department of Dermatology, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT 84103, USA. Email: kristina.duffin@hsc.utah.edu. Accepted for publication May 12, 2022.
James Solomon
K. Callis Duffin, MD, Department of Dermatology, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA; L.D. Mazzuoccolo, MD, MPH, M.J. Cura, MD, Department of Dermatology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; M. Esposito, MD, Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy; A.P. Fernandez, MD, PhD, Departments of Dermatology and Pathology, Cleveland Clinic, Cleveland, Ohio, USA; P. Gisondi, MD, Section of Dermatology and Venereology, University of Verona, Verona, Italy; A. Giunta, MD, Department of Dermatology, University of Rome Tor Vergata, Rome, Italy; T. Hillary, MD, Department of Dermatology, University Hospitals Leuven, Leuven, Belgium; S. Piaserico, MD, PhD, Unit of Dermatology, Department of Medicine, University of Padua, Padova, Italy; J.A. Solomon, MD, PhD, University Central Florida College of Medicine, and Florida State University College of Medicine, Orlando, Florida, and Carle-Illinois College of Medicine, Urbana, Illinois, USA; J.F. Merola, MD, MMSc, Division of Rheumatology and Immunology, Department of Dermatology and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. KCD received grants or is an investigator for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, BMS, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, and BI; is on the speaker's bureau for Novartis (nonpromotional only); and is on the consultant/advisory board for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, BMS, Stiefel, Novartis, Pfizer, Sienna, UCB, Ortho Dermatologic, and BI. LDM is a paid speaker for AbbVie, Elli Lilly, Novartis, Amgen, Janssen, UCB, and BI. MJC is a paid speaker for AbbVie, Janssen, and UCB. ME is a consultant/advisory board/invited speaker for Almirall, AbbVie, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Sanofi, and UCB. APF has received grants or is an investigator for Pfizer, Corbus, Mallinckrodt, AbbVie, and Novartis; on the speaker's bureau (nonpromotional only) for AbbVie, Novartis, Kyowa Kirin, and Mallinckrodt; and is on the consultant/advisory board for AbbVie, Alexion, BMS, Mallinckrodt, Novartis, and UCB. PG served as speaker and/or participated in advisory boards for AbbVie, Almirall, Amgen, Eli Lilly, Janssen, Novartis, Sanofi, Pfizer, and UCB. AG received grants or is an investigator for Biogen and Lilly; and is a consultant/advisory board/speaker for AbbVie, Almirall, Amgen, Biogen, Lilly, Sandoz, and UCB. TH has received grants or is an investigator/consultant for Amgen, AbbVie, Biogen, Celgene, Eli Lilly, Janssen, BMS, Novartis, Sandoz, Pfizer, UCB, Roche, and BI. SP is a consultant and/or speaker for AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, and UCB. JS is a consultant and/or investigator for Eli Lilly, GLG, LEO Pharma, Merck, Pfizer, Galderma, Parexel, UCB, Hedgepath, Mavis, BI, AbbVie, inVentiv, Sun Pharmaceutical, Mayne Pharma, Incyte, Arena, and PellePharm. JFM is a consultant and/or investigator for Merck, BMS, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres, and LEO Pharma. Address correspondence to Dr. K. Callis Duffin, Department of Dermatology, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT 84103, USA. Email: kristina.duffin@hsc.utah.edu. Accepted for publication May 12, 2022.
Joseph F. Merola
K. Callis Duffin, MD, Department of Dermatology, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA; L.D. Mazzuoccolo, MD, MPH, M.J. Cura, MD, Department of Dermatology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; M. Esposito, MD, Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy; A.P. Fernandez, MD, PhD, Departments of Dermatology and Pathology, Cleveland Clinic, Cleveland, Ohio, USA; P. Gisondi, MD, Section of Dermatology and Venereology, University of Verona, Verona, Italy; A. Giunta, MD, Department of Dermatology, University of Rome Tor Vergata, Rome, Italy; T. Hillary, MD, Department of Dermatology, University Hospitals Leuven, Leuven, Belgium; S. Piaserico, MD, PhD, Unit of Dermatology, Department of Medicine, University of Padua, Padova, Italy; J.A. Solomon, MD, PhD, University Central Florida College of Medicine, and Florida State University College of Medicine, Orlando, Florida, and Carle-Illinois College of Medicine, Urbana, Illinois, USA; J.F. Merola, MD, MMSc, Division of Rheumatology and Immunology, Department of Dermatology and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. KCD received grants or is an investigator for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, BMS, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, and BI; is on the speaker's bureau for Novartis (nonpromotional only); and is on the consultant/advisory board for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, BMS, Stiefel, Novartis, Pfizer, Sienna, UCB, Ortho Dermatologic, and BI. LDM is a paid speaker for AbbVie, Elli Lilly, Novartis, Amgen, Janssen, UCB, and BI. MJC is a paid speaker for AbbVie, Janssen, and UCB. ME is a consultant/advisory board/invited speaker for Almirall, AbbVie, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Sanofi, and UCB. APF has received grants or is an investigator for Pfizer, Corbus, Mallinckrodt, AbbVie, and Novartis; on the speaker's bureau (nonpromotional only) for AbbVie, Novartis, Kyowa Kirin, and Mallinckrodt; and is on the consultant/advisory board for AbbVie, Alexion, BMS, Mallinckrodt, Novartis, and UCB. PG served as speaker and/or participated in advisory boards for AbbVie, Almirall, Amgen, Eli Lilly, Janssen, Novartis, Sanofi, Pfizer, and UCB. AG received grants or is an investigator for Biogen and Lilly; and is a consultant/advisory board/speaker for AbbVie, Almirall, Amgen, Biogen, Lilly, Sandoz, and UCB. TH has received grants or is an investigator/consultant for Amgen, AbbVie, Biogen, Celgene, Eli Lilly, Janssen, BMS, Novartis, Sandoz, Pfizer, UCB, Roche, and BI. SP is a consultant and/or speaker for AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, and UCB. JS is a consultant and/or investigator for Eli Lilly, GLG, LEO Pharma, Merck, Pfizer, Galderma, Parexel, UCB, Hedgepath, Mavis, BI, AbbVie, inVentiv, Sun Pharmaceutical, Mayne Pharma, Incyte, Arena, and PellePharm. JFM is a consultant and/or investigator for Merck, BMS, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres, and LEO Pharma. Address correspondence to Dr. K. Callis Duffin, Department of Dermatology, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT 84103, USA. Email: kristina.duffin@hsc.utah.edu. Accepted for publication May 12, 2022.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Treatment of Psoriasis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
Kristina Callis Duffin, Luis Daniel Mazzuoccolo, María Julia Cura, Maria Esposito, Anthony P. Fernandez, Paolo Gisondi, Alessandro Giunta, Tom Hillary, Stefano Piaserico, James Solomon, Joseph F. Merola
The Journal of Rheumatology Nov 2022, jrheum.220316; DOI: 10.3899/jrheum.220316
Treatment of Psoriasis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
Kristina Callis Duffin, Luis Daniel Mazzuoccolo, María Julia Cura, Maria Esposito, Anthony P. Fernandez, Paolo Gisondi, Alessandro Giunta, Tom Hillary, Stefano Piaserico, James Solomon, Joseph F. Merola
The Journal of Rheumatology Nov 2022, jrheum.220316; DOI: 10.3899/jrheum.220316